Announcing CHI’s NGS-Based Assays in the Clinical Setting Conference, Aug. 19-20, 2014, DC

Managing the New Treatment Paradigm from Phenotype to Genotype
 
 
Spread the Word
Listed Under

Tags:
* Next-generation Sequencing
* Diagnostics
* Ngs
* Genetic Disorders
* Clinical

Industrys:
* Biotech
* Science

Location:
* Needham - Massachusetts - US

NEEDHAM, Mass. - May 7, 2014 - PRLog -- Cambridge Healthtech Institute (CHI) announced today the agenda for its Inaugural NGS-Based Assays in the Clinical Setting conference that will take place on August 19-20, 2014 at the Capital Hilton Hotel in Washington, DC, as part of the 6th annual Next Generation Dx Summit where 650+ global delegates will be in attendance. Robert Cooke-Deegan, M.D., of Duke University, will give the keynote presentation on ethical, legal, and policy issues surrounding sequencing.

Conference sessions include:
• Diagnosing genetic disorders with NGS
• Interrogating cancer genes with NGS and microarray
• NGS-based approaches to guide treatment
• Interpretation of results
• Making data actionable
• Next-generation sequencing diagnostics

Speakers include:
Sami S. Amr, Ph.D., Harvard Medical School; Partners Center for Personalized Genetic Medicine
Rong Chen, Ph.D., Icahn School of Medicine at Mount Sinai
Robert D. Daber, Ph.D., Bio-Reference Laboratories
Jennifer Dickey, RAC, Ph.D., US Food and Drug Administration
Andrea Ferreira-Gonzalez, Ph.D., Virginia Commonwealth University
Helen Fernandes, Ph.D., Weill Cornell Medical College
Jeremy Goecks, Ph.D., George Washington University
Wayne W. Grody, M.D., Ph.D., University of California Los Angeles School of Medicine
Madhuri Hegde, Ph.D., FACMG, Emory University School of Medicine
Christine M. Lovly, M.D., Ph.D., Vanderbilt Ingram Cancer Center
Elaine Lyon, Ph.D.,  ARUP
Raja Mazumder, Ph.D., The George Washington University
Jennifer Morrissette, Ph.D., University of Pennsylvania Perelman School of Medicine
Peter Nagy, Ph.D., Columbia University
Donald “Will” Parsons, M.D., Ph.D.,  Texas Children’s Cancer Center
Carol Saunders, Ph.D., FACMG, Children’s Mercy Hospital
Peter J. Tonellato, Ph.D., Beth Israel Deaconess Medical Center and Harvard Medical School

Writers and editors are invited to attend. To request a press pass, email Lisa Scimemi, lscimemi@healthtech.com.

For more information, visit http://www.NextGenerationDx.com/NGS-Based-Assays

About Next Generation Dx Summit
Access to next generation diagnostics will only be gained through careful creation and management of partnerships in the community around development, commercialization, reimbursement and regulation. This year’s Next Generation Dx Summit will showcase advances in personalized medicine through a comprehensive program encompassing companion diagnostics, infectious disease, cancer molecular markers, point-of-care, inherited disorders, cell free DNA and single cell sequencing. This event has become the meeting place for major players in the expanding arena of diagnostics. It will showcase key components of their successful adoption in the clinic and advancement to the market. http://www.NextGenerationDx.com

About Cambridge Healthtech Institute (CHI)
Cambridge Healthtech Institute (CHI), founded in 1992, is the industry leader in providing superior-quality scientific information to eminent researchers and business experts from top pharmaceutical, biotech, and academic organizations. Delivering an assortment of resources such as events, reports, publications and eNewsletters, CHI's portfolio of products include Cambridge Healthtech Institute Conferences, Barnett Educational Services, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners, Cambridge Healthtech Media Group, and The Knowledge Foundation. www.chicorporate.com

Contact
James Prudhomme
***@healthtech.com
End
Cambridge Healthtech Institute News
Trending
Daily News
Weekly News



Like PRLog?
9K2K1K
Click to Share